Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568461 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT03568461 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT03568461, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Interventions
- BIOLOGICAL tisagenlecleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568461
The ClinicalTrials.gov registry entry for NCT03568461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tisagenlecleucel is the first listed.
NCT03568461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03568461 about?
NCT03568461 is a clinical study titled "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma". This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
What is the current status of trial NCT03568461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2018-11-12. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT03568461?
The interventions under investigation include: tisagenlecleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03568461?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.